In the commercial pharma space, there are currently a couple of (once small, but now) rapidly-growing companies that are gaining heft by making lots of acquisitions. One is Valeant. Maybe I’ll take a look at them another day. The other is Actavis. Which was once Watson (mostly generic drugs). They bought up several companies with branded […]